BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 10989982)

  • 1. Chemoprevention of breast cancer.
    Brown PH; Lippman SM
    Breast Cancer Res Treat; 2000 Jul; 62(1):1-17. PubMed ID: 10989982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
    Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
    J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
    Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
    Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
    Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
    Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer.
    Anderson C; Nichols HB; House M; Sandler DP
    Cancer Prev Res (Phila); 2019 Nov; 12(11):801-808. PubMed ID: 31431499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer prevention trials.
    Rhodes DJ; Hartmann LC; Perez EA
    Curr Oncol Rep; 2000 Nov; 2(6):558-65. PubMed ID: 11122893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective estrogen receptor modulators in breast cancer prevention.
    Li F; Dou J; Wei L; Li S; Liu J
    Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprevention for high-risk women: tamoxifen and beyond.
    Fabian CJ; Kimler BF
    Breast J; 2001; 7(5):311-20. PubMed ID: 11906441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond.
    Bao T; Prowell T; Stearns V
    Am J Ther; 2006; 13(4):337-48. PubMed ID: 16858170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of breast cancer in the older patient.
    Minton SE
    Hematol Oncol Clin North Am; 2000 Feb; 14(1):113-30. PubMed ID: 10680075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
    Waters EA; McNeel TS; Stevens WM; Freedman AN
    Breast Cancer Res Treat; 2012 Jul; 134(2):875-80. PubMed ID: 22622807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
    Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
    J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention of breast cancer.
    Dalton RR; Kallab AM
    South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention or mastectomy for women at high risk of developing breast cancer.
    Sismondi P; D'Alonzo M; Pecchio S; Bounous VE; Robba E; Biglia N
    Maturitas; 2015 Nov; 82(3):271-3. PubMed ID: 26276104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention of breast cancer: implications for postmenopausal women.
    Fabian CJ; Kimler BF
    Drugs Aging; 2002; 19(1):43-78. PubMed ID: 11929326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
    Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
    Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort.
    Pinsky PF; Miller E; Heckman-Stoddard B; Minasian L
    Am J Obstet Gynecol; 2018 Jun; 218(6):606.e1-606.e9. PubMed ID: 29630889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer prevention.
    Powles TJ
    Oncologist; 2002; 7(1):60-4. PubMed ID: 11854547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.